If you work the line, you already compare options for a living. Which route to the call. Which tool for the door. Which hospital for this patient. Choosing where your own depression care happens deserves the same clear-eyed look, because the three main settings on offer are not variations on one theme. They are different in who is watching, what drugs are involved, and how they fit a shift schedule.
Below is a plain comparison of in-clinic care, at-home telehealth, and the hybrid in between, built for police, fire, and EMS. Alongside it are findings from 443 adults in ten Midwest states, surveyed this summer at our publisher's expense. The survey was of the general public, not responders specifically, so treat the figures as a picture of what ordinary people want, not a verdict on what you should choose. They come from the final validated data.
How the public split
Asked how they would want to receive a newer depression treatment such as ketamine or esketamine, respondents divided like this: a local in-person clinic led with 44 percent. Telehealth from home landed at 22 percent and a start-in-clinic, finish-at-home hybrid at 23 percent. The last 11 percent had no preference.
That puts the clinic, alone or as the first step, in the plans of two-thirds of people, 67 percent combined. Now to what each option actually means.
Option 1: In-person clinic
What happens there. Evaluation, therapy, medication management, and any treatment that legally requires supervision. That last category includes Spravato, an esketamine nasal spray that the FDA approved for depression standard antidepressants have failed to relieve. Every dose is given on site, followed by observation. IV ketamine, which is off-label for depression, is also given in clinics. Brain Recovery Centers lays out how a Spravato visit is structured.
Oversight. Highest of the three. A clinician is in the building if your blood pressure spikes or you feel disoriented.
Schedule fit. The hardest part for shift workers. A Spravato visit runs a couple of hours including monitoring, and the drive home has to be someone else's job, since you may not drive until after a night's sleep. Early treatment often means more than one visit a week.
Privacy. You will be seen walking in. Your records, though, stay protected by federal privacy law.
Coverage. Spravato is frequently covered with prior authorization. IV ketamine usually is not.
Good fit if: you want the FDA-approved option, you want someone watching, and you can arrange rides and schedule gaps.
Option 2: At-home telehealth
What happens there. Video visits for therapy and medication management, which are standard and useful. Also, separately, at-home ketamine programs, where a telehealth prescriber sends lozenges or tablets to your house.
Oversight. Lowest, especially for the ketamine programs. No clinician is physically present during a dose. Screening and follow-up range from careful to cursory depending on the company.
Schedule fit. Best of the three. You can often book around nights and days off.
Privacy. High on the surface. No one sees your truck in the lot.
Coverage. Video therapy and psychiatry are widely covered. At-home ketamine is almost always self-pay.
Good fit if: you are doing talk therapy or medication management and need maximum flexibility. For at-home ketamine specifically, bring the offer to your own doctor and get their read first.
Option 3: Clinic first, then home
What happens there. An in-person start, typically the evaluation and any supervised treatment, followed by follow-ups and therapy by video.
Oversight. High where it counts, lighter where it can be.
Schedule fit. A middle path. The heavy clinic weeks are front-loaded, then the load eases.
Privacy. Moderate. Fewer trips to a building, same records protections.
Coverage. Depends on what is done in each setting. Ask the practice to spell it out.
Good fit if: you want supervised care but know that a rigid weekly clinic schedule will not survive your rotation.
The side-by-side in one list
- Most oversight: clinic, then hybrid, then home.
- Easiest on a rotating schedule: home, then hybrid, then clinic.
- Where the FDA-approved option lives: clinic only, including the clinic phase of a hybrid.
- Most likely to be covered: clinic and hybrid care that uses approved treatments. At-home ketamine rarely is.
What the public weighted most
On the survey's two-factor priority question, insurance coverage ran far ahead of everything, picked by 85 percent. Being near home came a distant second, 43 percent. FDA approval took third place, 27 percent, ahead of fast results at 24 percent, while discretion drew 11 percent and a veterans-and-responders specialist drew 10 percent.
FDA approval also mattered on its own terms. Nearly six in ten respondents, 59 percent, said approval would settle the question or weigh heavily on it before they tried a treatment at all. For a responder weighing a telehealth ketamine offer against a clinic that provides Spravato, that is a useful gut check: most people in this sample cared whether the thing they were taking had been approved for what they were taking it for.
Questions that cut through any sales pitch
- Which drug, exactly, and is it FDA-approved for what I have, or off-label?
- Who is present during treatment, and what is the plan if something goes wrong?
- Which visits must be in person, and which can be video?
- Does my insurance cover this here, and who handles prior authorization?
- Can you work with a schedule that changes every few weeks?
The best choice is the one a clinician who knows your history agrees fits you. Nothing in this comparison is medical advice, and no setting can promise that a treatment will work.
If the job has worn you down to where suicide has started to cross your mind, reach out before your next tour. Dial or text the three digits 988 from any phone in the country. The Suicide and Crisis Lifeline answers every hour of every day, costs nothing, and the counselor on the other end is trained for exactly the kind of weight you carry.
Methodology
Commissioning and payment for this research came from the publisher. Pollfish fielded the questionnaire on its consumer panel through a June 23, 2026 close, with n=443 respondents, adults aged 18 to 64 in Nebraska, Illinois, Missouri, Ohio, Minnesota, Kansas, Indiana, Oklahoma, Wisconsin, and Iowa. We report whole-sample percentages only, because responders and veterans together numbered 29, too few for a group figure. All figures are final and validated.